Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine
The SHIELD-Utah study compared Novavax’s vaccine to the Pfizer/BioNTech mRNA 2024-2025 vaccine
Read Moreby Emily Kimber | Apr 22, 2025 | News | 0
The SHIELD-Utah study compared Novavax’s vaccine to the Pfizer/BioNTech mRNA 2024-2025 vaccine
Read MoreAn estimated 7.5 million people will be invited to receive the booster
Read Moreby Jen Brogan | Apr 17, 2024 | News | 0
The findings suggest why children tend to experience milder symptoms compared to older adults
Read Moreby Jen Brogan | Mar 1, 2024 | News | 0
Different factors, such as illness duration and virus variant, impacted patients cognitive abilities
Read Moreby Jen Brogan | Feb 8, 2024 | News | 0
The committee has advised that the vaccine should be given to those at the highest risk
Read Moreby Jen Brogan | Feb 2, 2024 | News | 0
Dopamine neuron senescence is a hallmark of Parkinson’s disease
Read Moreby Jen Brogan | Jan 29, 2024 | News | 0
A total of 103,277 general and acute beds are now available to NHS patients
Read Moreby Jen Brogan | Jan 2, 2024 | News | 0
The programme is the only remote, digital delivery nursing home training programme for dementia
Read Moreby Jen Brogan | Dec 11, 2023 | News | 0
New data highlights the inequalities in emergency hospital rates and vaccinations
Read Moreby Jen Brogan | Nov 20, 2023 | News | 0
The OpenSAFELY platform will support the discovery of new treatments
Read Moreby Jen Brogan | Sep 18, 2023 | News | 0
The updated vaccines more closely target current circulating variants
Read Moreby Jen Brogan | Sep 14, 2023 | News | 0
The funding will reduce waiting lists and ease the demand on the NHS during Winter
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479